» Articles » PMID: 20118910

Prevalence of TMPRSS2-ERG and SLC45A3-ERG Gene Fusions in a Large Prostatectomy Cohort

Overview
Journal Mod Pathol
Specialty Pathology
Date 2010 Feb 2
PMID 20118910
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

The majority of prostate cancers harbor recurrent gene fusions between the hormone-regulated TMPRSS2 and members of the ETS family of transcription factors, most commonly ERG. Prostate cancer with ERG rearrangements represent a distinct sub-class of tumor based on studies reporting associations with histomorphologic features, characteristic somatic copy number alterations, and gene expression signatures. This study describes the frequency of ERG rearrangement prostate cancer and three 5 prime (5') gene fusion partners (ie, TMPRSS2, SLC45A3, and NDRG1) in a large prostatectomy cohort. ERG gene rearrangements and mechanism of rearrangement, as well as rearrangements of TMPRSS2, SLC45A3, and NDRG1, were assessed using fluorescence in situ hybridization (FISH) on prostate cancer samples from 614 patients treated using radical prostatectomy. ERG rearrangement occurred in 53% of the 540 assessable cases. TMPRSS2 and SLC45A3 were the only 5' partner in 78% and 6% of these ERG rearranged cases, respectively. Interestingly, 11% of the ERG rearranged cases showed concurrent TMPRSS2 and SLC45A3 rearrangements. TMPRSS2 or SLC45A3 rearrangements could not be identified for 5% of the ERG rearranged cases. From these remaining cases we identified one case with NDRG1 rearrangement. We did not observe any associations with pathologic parameters or clinical outcome. This is the first study to describe the frequency of SLC45A3-ERG fusions in a large clinical cohort. Most studies have assumed that all ERG rearranged prostate cancers harbor TMPRSS2-ERG fusions. This is also the first study to report concurrent TMPRSS2 and SLC45A3 rearrangements in the same tumor focus, suggesting additional complexity that had not been previously appreciated. This study has important clinical implications for the development of diagnostic assays to detect ETS rearranged prostate cancer. Incorporation of these less common ERG rearranged prostate cancer fusion assays could further increase the sensitivity of the current PCR-based approaches.

Citing Articles

Roles and therapeutic potential of the SLC family in prostate cancer-literature review.

Fu Y, Chen J, Zhu X, Ding M, Wang H, Fu S BMC Urol. 2025; 25(1):32.

PMID: 39966814 PMC: 11837367. DOI: 10.1186/s12894-025-01714-w.


Linguistic networks uncover grammatical constraints of protein sentences comprised of domain-based words.

Shimpi A, Naegle K bioRxiv. 2024; .

PMID: 39677636 PMC: 11643033. DOI: 10.1101/2024.12.04.626803.


Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [Ga]Ga-PSMA-11 PET scans of primary prostate cancer.

Rupp N, Freiberger S, Ferraro D, Laudicella R, Heimer J, Muehlematter U Eur J Nucl Med Mol Imaging. 2024; 52(1):305-313.

PMID: 39083067 PMC: 11599624. DOI: 10.1007/s00259-024-06856-x.


as a possible novel predictive biomarker of chemotherapy response and death in pediatric B-cell ALL.

Torres-Llanos Y, Zabaleta J, Cruz-Rodriguez N, Quijano S, Guzman P, de Los Reyes I Front Mol Biosci. 2024; 11:1385140.

PMID: 38745909 PMC: 11091394. DOI: 10.3389/fmolb.2024.1385140.


Prostein expression in human tumors: a tissue microarray study on 19,202 tumors from 152 different Tumor entities.

Viehweger F, Bocker C, Weidemann S, Freytag M, Menz A, Buscheck F Diagn Pathol. 2024; 19(1):12.

PMID: 38218896 PMC: 10788021. DOI: 10.1186/s13000-023-01434-5.


References
1.
Bussemakers M, van Bokhoven A, Verhaegh G, Smit F, Karthaus H, Schalken J . DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59(23):5975-9. View

2.
Mosquera J, Mehra R, Regan M, Perner S, Genega E, Bueti G . Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009; 15(14):4706-11. PMC: 3717524. DOI: 10.1158/1078-0432.CCR-08-2927. View

3.
Laxman B, Morris D, Yu J, Siddiqui J, Cao J, Mehra R . A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008; 68(3):645-9. PMC: 2998181. DOI: 10.1158/0008-5472.CAN-07-3224. View

4.
Hessels D, Klein Gunnewiek J, van Oort I, Karthaus H, van Leenders G, van Balken B . DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003; 44(1):8-15; discussion 15-6. DOI: 10.1016/s0302-2838(03)00201-x. View

5.
Klezovitch O, Risk M, Coleman I, Lucas J, Null M, True L . A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A. 2008; 105(6):2105-10. PMC: 2538886. DOI: 10.1073/pnas.0711711105. View